NUVA Nuvasive Inc

Price (delayed)

$49.93

Market cap

$2.6B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.73

Enterprise value

$3.4B

NuVasive, Inc. is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. ...

Highlights
Nuvasive's net income has increased by 42% from the previous quarter and by 25% YoY
NUVA's EPS is up by 41% QoQ and by 26% YoY
The equity has contracted by 2.8% YoY but it has grown by 2.1% from the previous quarter
NUVA's quick ratio is down by 23% since the previous quarter and by 10% year-on-year

Key stats

What are the main financial stats of NUVA
Market
Shares outstanding
52.04M
Market cap
$2.6B
Enterprise value
$3.4B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.18
Price to sales (P/S)
2.23
EV/EBIT
N/A
EV/EBITDA
24.12
EV/Sales
2.93
Earnings
Revenue
$1.16B
EBIT
-$9.01M
EBITDA
$140.89M
Free cash flow
$37.81M
Per share
EPS
-$0.73
Free cash flow per share
$0.73
Book value per share
$15.68
Revenue per share
$22.35
TBVPS
$24.9
Balance sheet
Total assets
$2.16B
Total liabilities
$1.35B
Debt
$1.01B
Equity
$811.92M
Working capital
$543.49M
Liquidity
Debt to equity
1.24
Current ratio
3.19
Quick ratio
1.76
Net debt/EBITDA
5.67
Margins
EBITDA margin
12.2%
Gross margin
71.6%
Net margin
-3.2%
Operating margin
-1.1%
Efficiency
Return on assets
-1.7%
Return on equity
-4.6%
Return on invested capital
-0.5%
Return on capital employed
-0.5%
Return on sales
-0.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NUVA stock price

How has the Nuvasive stock price performed over time
Intraday
0.62%
1 week
1.38%
1 month
-12.6%
1 year
-26.58%
YTD
-4.86%
QTD
-11.94%

Financial performance

How have Nuvasive's revenue and profit performed over time
Revenue
$1.16B
Gross profit
$828.94M
Operating income
-$12.43M
Net income
-$37.38M
Gross margin
71.6%
Net margin
-3.2%
The company's operating income has shrunk by 156% YoY and by 3.4% QoQ
NUVA's operating margin has dropped by 152% year-on-year
The net margin has grown by 43% from the previous quarter and by 32% YoY
Nuvasive's net income has increased by 42% from the previous quarter and by 25% YoY

Growth

What is Nuvasive's growth rate over time

Valuation

What is Nuvasive stock price valuation
P/E
N/A
P/B
3.18
P/S
2.23
EV/EBIT
N/A
EV/EBITDA
24.12
EV/Sales
2.93
NUVA's EPS is up by 41% QoQ and by 26% YoY
NUVA's price to book (P/B) is 15% less than its 5-year quarterly average of 3.7 and 15% less than its last 4 quarters average of 3.7
The equity has contracted by 2.8% YoY but it has grown by 2.1% from the previous quarter
The price to sales (P/S) is 21% lower than the 5-year quarterly average of 2.8 and 18% lower than the last 4 quarters average of 2.7
Nuvasive's revenue has increased by 9% YoY

Efficiency

How efficient is Nuvasive business performance
NUVA's ROS has soared by 76% QoQ
The company's return on invested capital has surged by 76% QoQ
The return on assets has increased by 43% since the previous quarter and by 15% year-on-year
The company's return on equity rose by 41% QoQ and by 18% YoY

Dividends

What is NUVA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NUVA.

Financial health

How did Nuvasive financials performed over time
The total assets is 60% greater than the total liabilities
NUVA's quick ratio is down by 23% since the previous quarter and by 10% year-on-year
NUVA's current ratio is down by 20% since the previous quarter and by 8% year-on-year
The debt is 24% more than the equity
NUVA's debt to equity is up by 3.3% year-on-year but it is down by 2.4% since the previous quarter
The equity has contracted by 2.8% YoY but it has grown by 2.1% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.